Recursion Pharmaceuticals employs a sophisticated platform known as the Recursion Operating System (OS) to revolutionize drug discovery. This system integrates a vast array of biological and chemical datasets, exceeding 50 petabytes, to create comprehensive Maps of Biology and Chemistry. By leveraging advanced machine learning techniques, Recursion can identify and explore complex relationships between genes, compounds, and diseases, significantly enhancing the efficiency of the drug discovery process. The platform's iterative approach allows for continuous learning and improvement, as each experiment generates new data that refines future predictions, creating a virtuous cycle of discovery.

Central to Recursion's methodology is the use of high-dimensional imaging and phenomics, which involves analyzing microscopy images of human cells to extract meaningful biological data. This imaging capability, combined with the company's innovative software, LOWE, enables the orchestration of both wet-lab and dry-lab activities, streamlining the drug development process. By focusing on precision oncology and rare diseases, Recursion aims to accelerate the path to approval for new therapies, ultimately improving patient outcomes through a data-driven approach to biopharmaceutical development.

United States

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.

Cancer

Central Nervous System (CNS)

Nervous System Diseases

Recursion Pharmaceuticals

REC-4881

Clostridium difficile Colitis

REC-3964 is a potential first-in-class, orally bioavailable non-antibiotic small molecule that is being investigated for the potential treatment of recurrent Clostridioides difficile (C. diff.) infection. This selective inhibitor is Recursion’s first new chemical entity to reach the clinic, and binds and blocks catalytic activity of the toxin's innate glucosyltransferase. In preclinical studies, REC-3964 was found to be superior to bezlotoxumab in a human disease relevant C. diff. hamster model, with significant difference in probability of survival versus bezlotoxumab alone at the end of treatment. REC-3964 was also well tolerated in Phase 1 healthy volunteer studies, demonstrating potential safety and tolerability with no serious adverse events (SAEs)

REC-3964

Familial Adenomatous Polyposis

REC-4881 

REC-1245

Solid tumor/s

REC-617

Small cell lung cancer

REC-4539

Relapsed/ refractory lymphoma

REC-3565 is a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitor designed using Recursion’s AI-driven multi-parameter optimization approach. MALT1, a key protease in the NF-kB pathway, drives malignant B-cell proliferation in hematological cancers. While current therapies (e.g., BTK inhibitors) have advanced treatment, resistance remains a significant challenge. REC-3565 targets MALT1 to potentially overcome resistance and improve outcomes, either as a monotherapy or in combination with BTK and BCL2 inhibitors. 

REC-3565

Hypophosphatemia

REV102

Neurofibromatosis Type 2-mutated meningiomas

REC-2282 is a CNS-penetrant, orally bioavailable, small molecule pan-HDAC inhibitor being developed for the treatment of NF2-mutated &nbsp;meningiomas. This molecule appears to be well tolerated, including in &nbsp;patients dosed for multiple years, and potentially has reduced cardiac &nbsp;toxicity that would differentiate it from other HDAC inhibitors. Its &nbsp;oral bioavailability and CNS penetrance distinguish it from &nbsp;currently-approved HDAC inhibitors. REC-2282 has been granted Fast Track &nbsp;and Orphan Drug designations for NF2-mutated meningiomas by the U.S. Food and Drug Administration, as well as Orphan Drug designation for NF2-mutated meningiomas by the European Commission.

Recursion Pharmaceuticals

Company Details